
Please try another search
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Name | Age | Since | Title |
---|---|---|---|
Louis J. Aronne | 69 | 2015 | Member of Scientific Advisory Board |
Caroline M. Apovian | - | - | Member of Scientific Advisory Board |
Lee M. Kaplan | - | - | Member of Scientific Advisory Board |
Allan Geliebter | - | - | Member of Scientific Advisory Board |
Hassan M. Heshmati | 73 | 2020 | Member of Scientific Advisory Board |
Arne V. Astrup | - | - | Member of Scientific Advisory Board |
Angelo Tremblay | - | 2015 | Member of Scientific Advisory Board |
James Oakley Hill | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review